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S172 Oral Presentationsin HSCs and CMPs. A rise in BCR-ABL levels in GMP populations
signified impending relapse. Post-SCTpatients harboredmore resid-
ual CML cells in CD34+ subpopulations than TKI-treated patients.
Our findings suggest that in patients with persistent MRD-positivity
post-SCT, the graft-versus-leukemia (GVL) effect may eliminate
mature leukemic CD34+ subpopulations in vivo more readily. Prim-
itive leukemic HSCs and CMPs, although persistent, are presumably
constrained by GVL in patients who do not fulfill criteria for relapse.
Conversely, TKI reduces the number of BCR-ABL-positive GMPs
and CMPs more efficiently. Our data support adjuvant TKI-treat-
ment for CML relapse post-SCT, and concurrent vaccination strate-
gies which can target surface proteins on HSCs to eradicate CML.HEMATOPOIESIS/MESENCHYMAL CELLS47
TIE2 + BONE MARROW ENDOTHELIAL CELLS REGULATE HEMATOPOI-
ETIC RECONSTITUTION IN VIVO
Doan, P.L.1, Russell, J.L.1,Meadows, S.K.1, Himburg, H.A.1, Daher, P.1,
Chao, N.J.1, Kirsch, D.2, Chute, J.P.1 1Duke University Medical Center,
Durham, NC; 2Duke University Medical Center, Durham, NC
Radiation and chemotherapy cause myelosuppression in patients
via damage to bone marrow (BM) hematopoietic stem/progenitor
cells (HSCs). HSCs reside adjacent to BM sinusoidal vessels but
the function of BM endothelial cells (BM ECs) in regulating HSC
fate in vivo remains less well understood. We hypothesized that
BM ECs are critical in regulating BM hematopoietic reconstitution
following radiation stress. To test this hypothesis, we used Cre-
LoxP recombination to create targeted deletion of the pro-apoptotic
genes, Bak and Bax, in Tie2 + BM ECs (Tie2Cre;Bak-/-;BaxFl/-
mice) andmeasured hematopoietic response to total body irradiation
(TBI). Tie2Cre;Bak-/-;BaxFl/- mice were compared with Tie2Cre;
Bak-/-; BaxFl/+ mice which have constitutive Bak deletion but retain
Bax in Tie2 + BM ECs. After exposure to 100 cGy TBI, Tie2Cre;
Bak-/-;BaxFl/- mice displayed a 2-fold increase in total viable
BM cells (p5 0.04), 4-fold increase in BM ckit+sca+lineage- (KSL)
progenitor cells (p\0.0001), 3-fold increase in colony-forming
unit-spleen day 12 content (p5 0.0003) and a 2-fold increase in 12-
week competitive repopulating units (CRUs) (p5 0.002) compared
to Tie2Cre;Bak-/-;BaxFl/+ mice. Comparable radioprotection
was observed after 300 cGy TBI. Since Tie2 is expressed by BM
ECs and a subset of BM HSCs, we wanted to determine whether
the radioprotection we observed in Tie2Cre;Bak-/-;BaxFl/- mice
was caused autonomously by protection of Tie2 + BM ECs or
Tie2 +HSCs. We transplanted 4  106 BM cells from Tie2Cre;
Bak-/-;BaxFl/- mice into lethally irradiated (950 cGy) wild type
B6.SJL mice such that the recipient mice were chimeric for Bak and
Bax deletions only in hematopoietic cells while retaining a wild
type BM microenvironment, verified by qRTPCR. At 16 weeks
post-transplant, the chimeric recipient mice were then exposed to
100 and 300 cGy TBI and we compared the hematopoietic response
of these mice to that of Tie2Cre;Bak-/-;BaxFl/- mice. After 100 cGy
TBI, the hematopoietic response of the chimeric mice revealed a sig-
nificant reduction in total viable BM cells (1.3-fold), BM KSL cells
(7.4-fold) and 12-wk CRU weeks (1.6-fold, p5 0.008) compared to
100 cGy-irradiated Tie2creBak-/-;BaxFl/- mice. These results
demonstrate that Tie2 + BM ECs positively regulate hematopoietic
reconstitution following injury and indicate that BMECs are a novel
mechanistic target for therapies to augment hematopoietic recovery
in patients undergoing radiation and/or chemotherapy.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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PATIENT ETHNICITY MARKEDLY AFFECTS THE PROBABILITY OF FIND-
ING AN HLA-A, -B, -C, AND DRB1 ALLELE MATCHED UNRELATED DONOR
FOR HEMOPOIETIC CELL TRANSPLANTATION
Anasetti, C.1, Hillgruber, R.1, Nye, V.1, Ayala, E.1, Kharfan-
Dabaja, M.1, Fernandez, H.F.1, Field, T.1, Ochoa, J.L.1, Perez, L.E.1,Tomblyn, M.1, Benson, K.2, Davis, J.3, Dodson, K.3, Confer, D.3 1Moffitt
Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL;
3National Marrow Donor Program, Minneapolis, MN
The adult unrelated volunteer registries includemore then 14mil-
lion donors worldwide; however, the required precision of patient
and donor matching for high resolution HLA determinants, and
the ethnic variation of the patient population put a yet unknown con-
straint to the probability of finding a suitable donor. We evaluated
the results of unrelated searches for 398 consecutive patients.
Patients and donors were typed by HLA sequencing. Searches
were assisted by NMDP histocompatibility specialists for patients
to identify an HLA-A, B, C, DRB1 match (8/8) or a partial match
(7/8). HLA-DQB1 was considered in the search, but was not evalu-
ated in this analysis. For the purpose of this study, the search was
completed when confirmatory typing on a freshly drawn donor sam-
ple identified the first suitable donor. Such a donor was found for 336
(85%) patients after a median of 20 [95% C.I. 11-59] days: this was
an 8/8match for 209 (53%) patients and a 7/8 for 127 (32%) patients,
with no difference in search duration observed by matching grade.
With a 7/8, the mismatch was at -A (35%), -B (26%), -C (28%), or
-DRB1 (11%). The probability of finding a donor was not affected
by patient age or diagnosis, but was affected by the patient ethnicity.
An 8/8match was found for 181/293 (62%)Caucasians, 22/65 (34%)
Hispanics, and 6/40 (15%) African-Americans, and a 7/8 match was
found for 80 (27%) Caucasians, 28 (43%) Hispanics and 19 (48%)
African-Americans (p\0.0001). Therefore, only 11% of Caucasians
had no suitable donor compared to 23% of Hispanics and 37% of
African Americans.
Consistent with overall NMDP data, among those with a suitable
match, 161/336 (48%) patients reached transplantation after a
median of 101 [95% C.I.; 56-258] days from the search inception.
The interval from finding the first donor to transplant was a median
of 81 [95% C.I.: 45-199] days, about 4-fold longer than the search
itself. Reaching transplant was affected by the match grade, 107/
209 (51%) for 8/8, 54/127 (43%) for 7/8, and 3/62 (5%) for those
without a match (p\0.0001). The low probability of reaching trans-
plant despite a suitable donor is alarming: 40% deteriorated or died,
17% received other treatment modalities, 14% declined or failed to
make a decision, 14% waited for a better match, 16% other reasons.
A suitablymatched unrelated donor is available for the largemajority
of the patients, however, Hispanic or African-American ethnicity
represents a barrier to find a suitable donor.49
CAN HISTOCHECK ALGORITHM PREDICT HIGH-RISK HLA ALLELE MIS-
MATCH COMBINATIONS RESPONSIBLE FOR SEVERE ACUTE GRAFT-VER-
SUS-HOST DISEASE?
Askar, M.1, Sobecks, R.2, Makishima, H.3, Maciejewski, J.2,3 1Allogen
Laboratories; 2Taussig Cancer Center; 3Cleveland Clinic, OH
HLA polymorphism remains a major hurdle for hematopoietic
stem cell transplantation (HSCT). In 2004 Elsner et al (BMT) pro-
posed the ‘‘HistoCheck’’ web-based tool to estimate the allogeneic
potential between HLA-mismatched stem cell recipient/donor pairs
expressed as a matching score (dissimilarity score, DSS). DSS is
based on the structural data of HLA molecules and the functional
similarity of amino acids. A high DSS score represents high dissim-
ilarity between MHC molecules.
Objective:We sought to investigate the potential of DSS to predict
high-risk HLA allele mismatch combinations responsible for severe
acute graft-versus-host disease (aGvHDgrades III and IV) from data
recently published by Kawase et al, Blood, 2007 by comparing DSS
in low and high risk combinations.
Method:DSS were calculated for 110 HLA allele mismatch combi-
nations observed in 3830 donor/recipient pairs using the Histo-
Check tool available on the Web (WWW.histocheck.org). We
compared ranges and means of DSS among high risk versus low
risk allele combinations.
Results: An example of a higher risk combination is Cw*0303 (do-
nor) – 1502 (patient) that was observed in 25 pairs with HR of
3.22 (p\0.001). A lower risk combination containing the same re-
cipient allele but a different donor option is Cw*0801 – 1502 (ob-
served in 36 pairs) with HR of 1.59 (p5 0.19). DSS for these 2
Locus
aGvHD
Risk #A #P HR Range p Value Range DSS Range
DSS
Mean
A* Low 11 389 0.64-1.57 0.2-0.8 1.04-5.66 2.62
High 4 214 1.78-3.45 \0.001-0.003 1.04-4.3 2.39
B* Low 4 200 1.28-1.48 0.118-0.538 1.74-2.81 2.53
High 2 30 3-3.34 \0.001-0.015 1.06-1.06 1.06
Cw* Low 18 578 0.46-2.88 0.057-0.899 1.52-23.9 15.1
High 17 600 1.67-6.22 0.001-0.043 1.52-23.86 15.97
DRB1* Low 25 729 0.47-2.25 0.079-0.985 1.3-13.33 4.91
High 2 76 2.13-3.19 \0.001-0.003 4.02-10.41 7.22
DQB1* Low 24 900 0.57-1.58 0.062-0.98 0.24-20.61 10.37
High 3 114 1.75-2.81 0.002-0.017 1.38-20.61 13.74
Oral Presentations S173combinations are 13.88 and 15.33, respectively. The following table
summarizes DSS means and ranges for high and low risk combina-
tions.
(Table 1) #A: # of allele combinations analyzed by Histocheck
#P: # of donor/patient pairs that have all the analyzed combina-
tions
HR: Hazard Ratios of developing severe aGvHD
P values: for the corresponding estimated hazard risk
Conclusion: Our analysis demonstrates that means and ranges of
DSS were interchangeable among high and low risk allele combina-
tions within loci A, B, and Cw. In loci DRB1 and DQB1 DSS means
were higher in the high risk combinations but the ranges remain
overlapping. This analysis does not support selecting donors for
HSCT recipients on the basis of low HistoCheck scores.IMMUNE RECONSTITUTION50
CYTOTOXIC T LYMPHOCYTES (CTL) SPECIFIC FOR CMV, ADENOVIRUS,
AND EBV CAN BE GENERATED FROM NAIVE T CELLS FOR ADOPTIVE IM-
MUNOTHERAPY
Hanley, P.1, Savoldo, B.1, Cruz, C.R.1, Leen, A.M.1, Rodgers, J.2,
Liu, H.1, Gee, A.P.1, Heslop, H.E.1, Rooney, C.M.1, Brenner, M.K.1,
Shpall, E.J.3, Bollard, C.M.1 1Baylor College of Medicine, Houston, TX;
2Baylor College of Medicine, Houston, TX; 3M.D. Anderson Cancer Cen-
ter, Houston, TX
Adoptive immunotherapy with peripheral blood (PB)-derived
CMV/Ad/EBV-specific CTL generated from seropositive donors ef-
fectively prevents viral disease after Peripheral Blood StemCell Trans-
plant (PBSCT),but this optionhasnotbeen feasiblewhen thedonorT-
cells are naive. PBSCT fromCMV-seronegative (CMVneg) donors to
CMV-seropositive (CMVpos) recipients produces a high incidence of
CMV infection since donor T-cells are naı¨ve to this virus. Umbilical
cord blood (CB) is an important source of stem cells for allotransplant
patients lacking human leukocyte antigen (HLA)-matched donors. T-
cells inCBgrafts are, however, also virus-naı¨ve, leading tohigher infec-
tions rates with CMV, EBV, adenovirus (Ad) and other viruses. Irre-
spective of whether the naive T-cells are sourced from CB or
CMVneg PB, CTL generation for clinical use from these donors has
been unsuccessful. We have now overcome this problem and can rou-
tinely generate CMV, Ad and EBV specific CTL fromCB and CMV-
specific CTLs from seronegative PB for clinical use. We used an
Ad5f35CMVpp65 vector to transduceCBor PBderived dendritic cells
and stimulated virus-specific CTL in the presence of IL-7, IL-12 and
IL-15.Thiswas followed by 2 stimulationswith autologous EBV-lym-
phoblastoid cell lines (LCL) transduced with the same vector. CB-de-
rived CTL were predominantly CD8+ (mean 87%;range 81-94) and
had significant cytotoxicity against CMVpp65, Adhexon/penton and
LCL targets. In addition, we generated CMVpp65, Adhexon/penton
and LCL-specific responses from the PB of 4 CMVneg adult donors,
which produced a mean of 92 (range 50-126), 163 (range 69-293),
and 62 (range 37-86) SFC to CMVpp65 respectively. Neither CB
nor CMVneg-derived CTL responded to irrelevant peptides. Of
note, thevirus-specificT-cells expanded fromCBandCMVnegdonorsderivedonly fromT-cellswithanaivephenotype (CD45RA+/CCR7+).
Moreover, both CB and CMVneg-derived CTL recognized ‘‘uncon-
ventional’’ CMVpp65 epitopes, as identified by overlapping pp65 pep-
tide pools and confirmed by IFN-g ELISPOT as well as multimer
analysis. In HLA-A2+ subjects, naive-derived CTL did not recognize
conventional HLA-A2 associated CMV pp65 epitopes such as NLV,
suggesting an inherent differencebetweennaı¨ve andmemoryT-cell re-
sponses to CMV. In summary, virus-specific responses T-cell re-
sponses can be obtained even from CB and virus-naive adult donors
andmayallowpreventionand treatmentof viraldisease in the recipients
of these allografts.
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DENDRITIC CELL FACILITATE THYMIC RECOVERY AND ENHANCE IM-
MUNE RECONSTITUTION AFTER HEMATOPOIETIC STEM CELL TRANS-
PLANT
Langfitt, D., Wallace, N., Dallas, M.H. St Jude Children’s Research
Hospital, Memphis, TN
After hematopoietic stem cell transplantation (HSCT), the first
committed cells to engraft in the thymus are dendritic cells (DCs).
The role of thymic DCs in T cell production by ensuring efficient
tolerance and selection has been well demonstrated, however the
role of thymic DCs in facilitating donor engraftment has not been
investigated. Here we show addition of ex-vivo generated DCs
accelerates thymic engraftment as well as enhance T cell recovery
after HSCT. Control group received 103 lin-sca-1+c-kit+ (LSK)
(CD45.2) hematopoietic stem cell progenitors while the DCs group
received 103 LSK (CD45.2) cells along with 103 ex-vivo generated
DCs. DCs were generated using bone marrow from GFP+ CD57/
Bl mice (CD45.1/GFP+) and cultured for 7 days with GMCSF. On
the day of HSCT, C57/BL (CD45.1) recipients received lethal radi-
ation at 1000 cGy. At 4 and 7 days after HSCT, thymuses of theDCs
group had GFP+ CD11c+ cells present in the medullary region con-
firmed by immunohistochemistry and contained 1.8 and 4.2- fold,
respectively, higher number of thymocytes compared to control
group (p\0.05). Furthermore, thymuses of the DCs group showed
a 3.2 and 7.4-fold, respectively, higher number of thymoctyes
derived from donor LSK (CD45.2) cells compared to the control
group (p\0.05 and p\0.007). Two and four weeks after HSCT,
peripheral blood of DCs group contained at least 2.6 and 4.8-fold,
respectively, higher numbers of CD3+ cells derived from donor
LSK (CD45.2) cells compared to the control group (p\0.05).
Here, we demonstrate that ex-vivo generatedDCs efficientlymigrate
and home to the thymic medulla and hasten thymic recovery as dem-
onstrated by the higher number of total thymoctyes. Furthermore,
DCs facilitate thymic engraftment as shown by increase number of
donor thymoctyes. Lastly, recipients of DCs have earlier generation
of de-novo donor derived CD3+ T cells in the peripheral blood. By
using the GFP+ (CD45.1) cells along with donor LSK (CD45.2),
we were able to confirm that the facilitation of early thymic recovery
was due to the increased engraftment of the donor cells rather than
autologous recovery of the host. Thus, this study suggests that
DCs committed prior to thymic entry maintains the ability to
home to the medullary region and facilitate thymoctye recover and
hasten immune reconstitution after HSCT.52
CD40-ACTIVATED B CELLS MIGRATE TOWARDS SECONDARY LYMPHOID
ORGANS AND INTERACT DYNAMICALLY WITH T CELLS
Klein-Gonzalez, N.1, Balkow, S.2, Kondo, E.1, Grabbe, S.2, Liebig, T.1,
Shimabukuro-Vornhagen, A.1, Bloch, W.3, von Bergwelt-Baildon, M.1
1University Hospital of Cologne, Germany; 2 Johannes GutenbergUniver-
sity, Mainz, Germany; 3Deutsche Sporthochschule Ko¨ln, Germany
B cells have been demonstrated to present antigen to T cells in
vivo. CD40-activation dramatically improves antigen presentation
by normal and malignant B cells and has therefore been studied as
an approach to generate autologous ‘‘non-artificial’’ antigen present-
ing cells for active immunotherapy. Furthermore, CD40-B cells have
recently been shown to expand tumorantigen and viral specific CTL
